Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00637793 · ClinicalTrials.gov registry record · Phase 2
Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome
A Phase 2 study, sponsored by TorreyPines Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00637793 is a Phase 2 study that has completed, run by TorreyPines Therapeutics. The registered enrollment target is 24 participants.
The verdict
NCT00637793, a Phase 2 study, has completed, sponsored by TorreyPines Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of NGX267 in the improvement of decreased salivary flow associated with primary or secondary Sjögren's syndrome. For each patient, the study includes four periods of treatment separated by a washout period that may range from 4 - 8 days according to patient and site discretion. Each treatment period includes two overnight stays in the clinic. One dose of study drug is taken during each treatment period
Interventions
- DRUG NGX267
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00637793
The ClinicalTrials.gov registry entry for NCT00637793 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TorreyPines Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NGX267 is the first listed.
NCT00637793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00637793 about?
NCT00637793 is a clinical study titled "Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome". The purpose of this study is to evaluate the effectiveness of NGX267 in the improvement of decreased salivary flow associated with primary or secondary Sjögren's syndrome. For each patient, the study includes four periods of treatment separated by a washout period that may range from 4 - 8 days acc...
What is the current status of trial NCT00637793?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2008-02. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00637793?
The interventions under investigation include: NGX267 (DRUG).
Who is sponsoring clinical trial NCT00637793?
This trial is sponsored by TorreyPines Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.